Chest Wall Tumor Therapeutics Market Size, Share, and Industry Analysis, By Cancer Type (Primary Chest Wall Tumor {Chondrosarcoma, Osteosarcoma, Ewing’s sarcoma, Malignant fibrous histiocytoma, Rhabdomyosarcoma, Others}, and Secondary Chest Wall Tumor), By Therapy Type (Chemotherapy, Targeted Therapy, and Immunotherapy), By Route of Administration (Oral and Parenteral) By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Others), and Regional Forecast, 2026-2034

The chest wall tumor therapeutics market is rising rapidly. Chest wall tumors refer to a type of cancer that involves both the primary tumors that originate from the chest wall, such as the ribs, sternum, cartilage, and soft tissues, and the secondary tumors that are malignant and involve other forms of cancers, such as the breast or lung. The chest wall tumors therapeutics market is likely to witness significant growth due to the increasing prevalence of chest wall-associated tumors.

• For instance, as per the American Cancer Society, Cancer Statistics 2024, the osteosarcoma incidence rate is around 4.3 per million individuals from birth up to 14 years of age.

Additionally, emphasis on key biopharmaceutical and pharmaceutical companies to offer advanced products for treatment, with a strong focus on research and development activities, is expected to boost the chest wall tumor therapeutics market growth.

Chest Wall Tumor Therapeutics Market Driver

Increasing Prevalence of Chest Wall Tumors is Driving Market Growth

The increasing prevalence of primary tumors such as chondrosarcoma, osteosarcoma, and Ewing’s sarcoma, as well as the rising incidence of breast, lung, and pleural cancers, is also increasing the burden on the global healthcare systems and is also adding to the therapeutic burden. 

• For instance, as per the data published by NIH, in March 2023, chondrosarcoma accounts for 20 to 30% of all skeletal sarcomas, and per year, an estimated incidence of 1 in 200,000 occurs in the U.S. Such scenarios increase the demand for adequate diagnosis and treatment and thus drive the market growth.

Newly Diagnosed Cases of Lung Cancer in the U.S., 2019 & 2023

According to the American Lung Association, in 2019, 221,097.0 people were diagnosed with lung cancer in the U.S., which increased to 238,000.0 in 2023.

Chest Wall Tumor Therapeutics Market Restraint

Surgical Dominance for Chest Wall Tumor Treatment to Hamper Market Growth

High dependency for surgical removal of tumors associated with the chest wall is a significant restraint on the global chest wall tumor therapeutics market. The patients' shift toward surgery is due to the complex nature of this tumor, and surgery helps to completely remove the tumor, which offers the best chance of cure. Along with this, some of the chest wall tumors are resistant to chemotherapy and radiation, thus making surgery a preferred choice. Such conditions may decrease the adoption of therapeutics and hamper the market growth.

• For instance, as per the data published by MDPI, in October 2023, a retrospective descriptive study was performed at the Department of Thoracic Surgery, University Hospital of Zurich, to analyze the patients who were surgically treated for chest wall sarcoma between 1999 and 2018. Among the 44 patients who underwent chest wall resection for primary sarcoma, 18 patients (41.0%) were treated with surgery alone, while 10 patients (23.0%) received additional chemoradiotherapy. A smaller group of 3 patients (7.0%) underwent surgery combined with chemotherapy, and 13 patients (30.0%) received surgery with adjuvant radiotherapy. This distribution showcased the reliance on surgical intervention, thus hampering the adoption of drugs and market growth.

Chest Wall Tumor Therapeutics Market Opportunity

Currently, there are limited treatment options for different chest wall tumors such as Ewing's sarcoma.
Limited treatment options create unmet medical needs, leading to the development of new therapeutics for untapped chest wall tumors, which present significant market growth opportunities. 

• For instance, in April 2025, researchers at the UNC Lineberger Comprehensive Cancer Center designed and developed a novel therapeutic molecule, d(GGAA)3s, that targets ETV6 developed in Ewing sarcoma. This is a rare and aggressive cancer of the bone and soft tissue that primarily affects children and teenagers. Such development of targeted therapeutic improves treatment efficacy and reduces side effects associated with traditional chemotherapy and radiation. Thus expected to catalyze the market growth.

Key Insights

• The report covers the following key insights:
• Prevalence of Key Chest Wall Tumors, By Key Countries/Regions, 2024
• Pipeline Analysis, By Key Players 
• Epidemiology of Different Types of Chest Wall Tumors
• Reimbursement Scenarios, By Key Countries/ Regions
• New Product Launches/Approvals by Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

Analysis by Cancer Type

By type, the market is divided into primary chest wall tumor {chondrosarcoma, osteosarcoma, Ewing’s sarcoma, malignant fibrous histiocytoma, rhabdomyosarcoma, others}, and secondary chest wall tumor.

The primary chest wall sarcoma held a significant share of the market. The significant share of the segment is augmented by the increasing incidence of chest wall tumors and the rising demand for therapeutics for patients who are not eligible for surgery. 

Furthermore, increasing research and development activities by key players of the market to develop new therapeutic options for primary chest wall tumors are propelling the segment’s growth in the market.

For instance, in January 2025, GSK plc received Breakthrough Therapy Designation for the GSK5764227 candidate, which is a B7-H3-targeted antibody-drug conjugate (ADC) evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma (bone cancer).

Analysis by Therapy Type 

By therapy type, the market is divided into chemotherapy, targeted therapy, and immunotherapy.

The targeted therapy held a significant share of the market. The significant share of the segment is due to its nature of selectively attacking the cancer cells while minimizing damage to normal cells. This treatment often focuses on genetic mutations that turn healthy cells into cancer cells, thus acting as an effective treatment for chest wall tumors. Furthermore, increasing approvals and launches of the targeted therapies are expected to boost the growth of the segment in the market.

For instance, in December 2024, Eugia Pharma Specialities received the U.S.FDA approval for the manufacturing and commercialization of Pazopanib Tablets, 200 mg. This is a targeted therapy used for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in adults who have received prior chemotherapy.

Analysis by Route of Administration 

By route of administration, the market is divided into oral and parenteral.

The oral segment is expected to dominate the market. The growth of the segment is driven by increasing patient preference due to ease of administration and adherence to treatment regimes. As well as it is becoming a significant trend for the adoption of the medication for those patients who aren’t eligible for surgery. Such factors are expected to propel the segment’s growth in the market.

For instance, in April 2025, Bayer AG received U.S. FDA approval for VITRAKVI (larotrectinib) capsules, a TRK inhibitor for the treatment of adult and pediatric patients with solid tumors. Such approvals boost the segment’s growth in the forecast period. 

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, specialty pharmacies, and others. 

The specialty pharmacy segment held a substantial portion of the market. The increasing development of cell and gene therapy for cancer treatment, and the increasing focus on expanding its availability for patients in need. Thus, specialty pharmacies fulfill the demand for affordable services for patients with personalized customer service that supports patient adherence to medication plans. Moreover, the launch of new advanced specialty pharmacies to bolster the segment’s growth.

For instance, in April 2025, Walgreens announced the expansion of its specialty pharmacy services with the launch of Walgreens Specialty Pharmacy. This pharmacy aimed to enhance patient care and increase value for payers and partners. Also, to support patients with complex, chronic conditions and offer advanced treatments such as gene and cell therapy.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a significant share of the global chest wall tumor therapeutics market in 2024. The major share of the region is augmented by the rising prevalence of cancer, such as breast, lung, and bone cancer. Furthermore, the region comprises of advanced healthcare infrastructure that facilitates early diagnosis and effective management of chronic illnesses. Also, the region has comprehensive reimbursement policies that simplify access to advanced treatments and therapies. 

Moreover, the presence of major pharmaceutical and biopharmaceutical companies, which emphasis research and developing innovative products, is driving the region's market growth.

In August 2024, the U.S Food and Drug Administration (FDA) approved Tecelra, a gene therapy used to treat unresectable or metastatic synovial sarcoma in adults who have received prior chemotherapy.

Europe has a substantial share of the chest wall tumor therapeutics market. The rising prevalence of chest wall tumors and malignant tumors associated with them. Additionally, the presence of advanced facilities and government support for the treatment of such diseases to propel the region's growth in the market.

Moreover, the Asia Pacific is expected to grow with a significant CAGR during the forecast period. Increasing approval and product launches by the regional players for the chest wall tumor treatment to bolster the segment’s growth.

For instance, in December 2024, China’s National Medical Products Administration (NMPA) approved taletrectinib adipate (Dovbleron), a ROS1 TKI, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC).

Key Players Covered

The global chest wall tumor therapeutics market is reflecting a fragmented competitive landscape, with a large number of established and emerging providers. The report includes the profiles of the following key players:

• Merck & Co., Inc. (U.S.)
• Eli Lilly (U.S.)
• GSK plc (U.K.)
• Eisai Co., Ltd. (Japan)
• Epizyme, Inc. (U.S.)
• Adaptimmune (U.K.)
• Bristol-Myers Squibb (U.S.)

Key Industry Developments

• July 2025: Actuate Therapeutics, Inc. Actuate Therapeutics announced the completion of Phase 1 of its clinical trial for elraglusib alone or with other chemotherapy agents in children with hard-to-treat cancers. The trial showed promising activity, especially in refractory Ewing Sarcoma. With these results, the company moved forward with a Phase 2 study targeting relapsed/refractory Ewing Sarcoma in children, adolescents, and adults.
• May 2024: Zentalis Pharmaceuticals Inc. announced the final results from its Phase 1 trial of azenosertib and gemcitabine in relapsed or refractory (R/R) osteosarcoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.